Clinical trials: Retinal Vein Occlusion (RVO), active
Retinal Vein Occlusion (RVO)
Robotic RVO Trial: Robot-assisted Retinal Vein Cannulation in Patients With Retinal Vein Occlusions
Retinal vein occlusions (RVOs) are the second leading cause of permanent vision loss in the UK. Current treatments, like anti-VEGF injections or steroids, address complications such as macular fluid but do not target the…
- Trial name
- RVO (NCT07820761)
- Testing
- Surgery with Preceyes Robot plus NHS standard of care
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Oxford
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)
A Phase I Study of GenSci148 Intravitreal Injection for Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion
This is a Phase I, multicenter, open-label, dose-escalation study conducted in two parts to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GenSci148 administered via intravitreal (IVT)…
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
- Trial name
- GenSci148-101 (NCT07817615)
- Testing
- GenSci148 Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.
The main goal of this study is to find out how common certain eye diseases are in Germany and how they have changed over time. The diseases being studied are: nAMD (neovascular age-related macular degeneration): a condition that…
- Trial name
- NCT07308639
- Testing
- anti-VEGF medication
- Where
- Germany
- Volunteers
- 50,000 people
- Sponsor
- Bayer
DME, Retinal Vein Occlusion (RVO)
AI vs. Physician for Anti-VEGF Decision-Making: An RCT
We developed an artificial intelligence system, called QiLin, which was designed to assist anti-VEGF treatment decisions in retinal diseases.
- Conditions
- DME, Retinal Vein Occlusion (RVO), Neovascular (Wet) Age-Related Macular Degeneration
- Trial name
- NCT07328776
- Testing
- QiLin-assisted, physician only, without QiLin assisted
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
no Obvious Abnormalities, Diabetic Retinopathy (DR)
Retinal Clinical Assessment With AI-derived Quantitative Information
This randomized controlled trial evaluates whether providing clinicians with AI-derived quantitative retinal information improves the quality and efficiency of retinal clinical assessment.
- Conditions
- no Obvious Abnormalities, Diabetic Retinopathy (DR), AMD, Cup-to-disc Ratio Bigger Than 0.5
- Trial name
- NCT07291960
- Testing
- AI-derived retinal quantitative information-assisted reporting
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Beijing Tongren Hospital
Retinal Vein Occlusion (RVO)
Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment
Retinal vein occlusion (RVO), a common retinal vascular disease, is frequently treated with anti-vascular endothelial growth factor (anti-VEGF) agents as first-line therapy.
- Trial name
- NCT07133438
- Testing
- Anti-VEGF drug, Mecobalamin 5 MG
- Where
- China
- Volunteers
- 120 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Diabetic Retinopathy (DR), Retinal Vein Occlusion (RVO)
High-throughput Large-model-based AI-assisted Diagnosis Using OCT
This observational study aims to establish key technologies for high-throughput, large-model-based AI-assisted diagnosis using optical coherence tomography (OCT) and OCT angiography (OCTA).
- Conditions
- Diabetic Retinopathy (DR), Retinal Vein Occlusion (RVO), Age-Related Macular Degeneration (AMD), Pathologic Myopia
- Trial name
- NCT07249307
- Testing
- No intervention
- Volunteers
- 2,000 people
- Sponsor
- Peking Union Medical College Hospital